This technology is a therapeutic for social isolation-induced anxiety in females by regulating arginine vasopressin (Avp) and its receptor AVPR1A in the central amygdala.
Social isolation increases anxiety and obsessive-compulsive disorder (OCD)-like behaviors, and studies suggest that women are at higher risk of social isolation-induced anxiety. Despite treatment advancements, anxiety-related disorders remain the most prevalent mental disorders, significantly impairing individuals and impacting public health. To address these anxiety phenotypes, there is a critical need for targeted therapeutics for more personalized and effective treatment of anxiety disorders.
This technology mitigates social isolation-induced anxiety in females by regulating the arginine vasopressin (Avp) system and its receptor, AVPR1A. Social isolation leads to an increased expression of Avp and AVPR1A specifically in the amygdala of female mice, suggesting a gender-specific response. To address this, the technology employs compositions and methods such as AVPR1A antagonists (e.g., SRX246) to block the AVPR1A pathway, reducing anxiety and OCD-like behaviors. In addition, antisense oligonucleotides targeting AVPR1a pathways could be effective anxiolytics.
This technology has been validated with mouse models.
Patent Pending (WO/2023/164710)
IR CU21294
Licensing Contact: Kristin Neuman